Skip to main content
. 2019 Aug;14(8):1445–1448. doi: 10.4103/1673-5374.253528

Figure 2.

Figure 2

Frequency (%) of therapeutic use of ranibizumab in the most common retinal diseases.

The utilization of ranibizumab is more frequent in AMD than in DR, but it is subjected to a reduction over time. AMD: Age-related macular degeneration; DR: diabetic retinopathy.